Lipoprotein (a) and cardiovascular risk

The show must go on

Niki Katsiki, Khalid Al-Rasadi, Dimitri P. Mikhailidis

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Lipoprotein (a) [Lp(a)] is an independent but moderate, predictor for coronary heart disease (CHD) prevalence and severity. Several established and emerging cardiovascular (CV) risk factors including age, gender, ethnicity, smoking, dyslipidemia, hypertension, obesity, type 2 diabetes mellitus, alcohol consumption, arterial stiffness and hyperuricemia have been linked to Lp(a) metabolism. Apart from CHD, Lp(a) has been also associated with non-cardiac vascular diseases and diseases associated with increased CV risk such as chronic kidney disease, metabolic syndrome, non-alcoholic fatty liver disease, erectile dysfunction, obstructive sleep apnea syndrome, inflammatory bowel diseases and human immunodeficiency virus infection. The above data are discussed in the present narrative review. Several guidelines suggest the clinical use of Lp(a) in (re) defining vascular risk, especially in asymptomatic individuals at intermediate or high CV risk and those with a family history of premature CHD. By improving individuals risk stratification, Lp(a) may contribute to a better secondary prevention strategy. However, there is still a need to establish a standardized method to measure Lp(a) as well as selective potent therapies for lowering Lp(a). This will support conducting large randomized trials in order to establish whether lowering circulating Lp(a) levels will result in a significant reduction in CV events.

Original languageEnglish
Pages (from-to)989-1006
Number of pages18
JournalCurrent Medicinal Chemistry
Volume24
Issue number10
DOIs
Publication statusPublished - Mar 1 2017

Fingerprint

Lipoprotein(a)
Coronary Disease
Hyperuricemia
Vascular Stiffness
Obstructive Sleep Apnea
Erectile Dysfunction
Virus Diseases
Medical problems
Dyslipidemias
Secondary Prevention
Chronic Renal Insufficiency
Vascular Diseases
Viruses
Inflammatory Bowel Diseases
Metabolism
Alcohol Drinking
Liver
Type 2 Diabetes Mellitus
Blood Vessels
Obesity

Keywords

  • Cardiac diseases
  • Cardiovascular risk
  • Lipoprotein (a)
  • Non-cardiac vascular diseases
  • Vascular risk factors

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Lipoprotein (a) and cardiovascular risk : The show must go on. / Katsiki, Niki; Al-Rasadi, Khalid; Mikhailidis, Dimitri P.

In: Current Medicinal Chemistry, Vol. 24, No. 10, 01.03.2017, p. 989-1006.

Research output: Contribution to journalReview article

Katsiki, Niki ; Al-Rasadi, Khalid ; Mikhailidis, Dimitri P. / Lipoprotein (a) and cardiovascular risk : The show must go on. In: Current Medicinal Chemistry. 2017 ; Vol. 24, No. 10. pp. 989-1006.
@article{c103eafe56394f4d9176cc1b83f9ddf4,
title = "Lipoprotein (a) and cardiovascular risk: The show must go on",
abstract = "Lipoprotein (a) [Lp(a)] is an independent but moderate, predictor for coronary heart disease (CHD) prevalence and severity. Several established and emerging cardiovascular (CV) risk factors including age, gender, ethnicity, smoking, dyslipidemia, hypertension, obesity, type 2 diabetes mellitus, alcohol consumption, arterial stiffness and hyperuricemia have been linked to Lp(a) metabolism. Apart from CHD, Lp(a) has been also associated with non-cardiac vascular diseases and diseases associated with increased CV risk such as chronic kidney disease, metabolic syndrome, non-alcoholic fatty liver disease, erectile dysfunction, obstructive sleep apnea syndrome, inflammatory bowel diseases and human immunodeficiency virus infection. The above data are discussed in the present narrative review. Several guidelines suggest the clinical use of Lp(a) in (re) defining vascular risk, especially in asymptomatic individuals at intermediate or high CV risk and those with a family history of premature CHD. By improving individuals risk stratification, Lp(a) may contribute to a better secondary prevention strategy. However, there is still a need to establish a standardized method to measure Lp(a) as well as selective potent therapies for lowering Lp(a). This will support conducting large randomized trials in order to establish whether lowering circulating Lp(a) levels will result in a significant reduction in CV events.",
keywords = "Cardiac diseases, Cardiovascular risk, Lipoprotein (a), Non-cardiac vascular diseases, Vascular risk factors",
author = "Niki Katsiki and Khalid Al-Rasadi and Mikhailidis, {Dimitri P.}",
year = "2017",
month = "3",
day = "1",
doi = "10.2174/0929867324666170112111948",
language = "English",
volume = "24",
pages = "989--1006",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "10",

}

TY - JOUR

T1 - Lipoprotein (a) and cardiovascular risk

T2 - The show must go on

AU - Katsiki, Niki

AU - Al-Rasadi, Khalid

AU - Mikhailidis, Dimitri P.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Lipoprotein (a) [Lp(a)] is an independent but moderate, predictor for coronary heart disease (CHD) prevalence and severity. Several established and emerging cardiovascular (CV) risk factors including age, gender, ethnicity, smoking, dyslipidemia, hypertension, obesity, type 2 diabetes mellitus, alcohol consumption, arterial stiffness and hyperuricemia have been linked to Lp(a) metabolism. Apart from CHD, Lp(a) has been also associated with non-cardiac vascular diseases and diseases associated with increased CV risk such as chronic kidney disease, metabolic syndrome, non-alcoholic fatty liver disease, erectile dysfunction, obstructive sleep apnea syndrome, inflammatory bowel diseases and human immunodeficiency virus infection. The above data are discussed in the present narrative review. Several guidelines suggest the clinical use of Lp(a) in (re) defining vascular risk, especially in asymptomatic individuals at intermediate or high CV risk and those with a family history of premature CHD. By improving individuals risk stratification, Lp(a) may contribute to a better secondary prevention strategy. However, there is still a need to establish a standardized method to measure Lp(a) as well as selective potent therapies for lowering Lp(a). This will support conducting large randomized trials in order to establish whether lowering circulating Lp(a) levels will result in a significant reduction in CV events.

AB - Lipoprotein (a) [Lp(a)] is an independent but moderate, predictor for coronary heart disease (CHD) prevalence and severity. Several established and emerging cardiovascular (CV) risk factors including age, gender, ethnicity, smoking, dyslipidemia, hypertension, obesity, type 2 diabetes mellitus, alcohol consumption, arterial stiffness and hyperuricemia have been linked to Lp(a) metabolism. Apart from CHD, Lp(a) has been also associated with non-cardiac vascular diseases and diseases associated with increased CV risk such as chronic kidney disease, metabolic syndrome, non-alcoholic fatty liver disease, erectile dysfunction, obstructive sleep apnea syndrome, inflammatory bowel diseases and human immunodeficiency virus infection. The above data are discussed in the present narrative review. Several guidelines suggest the clinical use of Lp(a) in (re) defining vascular risk, especially in asymptomatic individuals at intermediate or high CV risk and those with a family history of premature CHD. By improving individuals risk stratification, Lp(a) may contribute to a better secondary prevention strategy. However, there is still a need to establish a standardized method to measure Lp(a) as well as selective potent therapies for lowering Lp(a). This will support conducting large randomized trials in order to establish whether lowering circulating Lp(a) levels will result in a significant reduction in CV events.

KW - Cardiac diseases

KW - Cardiovascular risk

KW - Lipoprotein (a)

KW - Non-cardiac vascular diseases

KW - Vascular risk factors

UR - http://www.scopus.com/inward/record.url?scp=85021117306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021117306&partnerID=8YFLogxK

U2 - 10.2174/0929867324666170112111948

DO - 10.2174/0929867324666170112111948

M3 - Review article

VL - 24

SP - 989

EP - 1006

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 10

ER -